Arovella Therapeutics Limited

ALA

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. The firm is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The firm's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The firm is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.

Aml3D Limited

AL3

AML3D Ltd. engages in the provision of 3D printing services and machinery. The company is disrupting metal part supply chains using the Company’s patented wire additive manufacturing (WAM) process. WAM combines state-of-the-art welding science, robotics automation, materials engineering, and proprietary software to lead metal additive manufacturing globally. The company is the original equipment manufacturer (OEM) of the ARCEMY industrial metal 3D printing systems. ARCEMY uses WAM to provide advanced, automated, point-of-need 3D manufacturing solutions that are efficient, cost-effective and have ESG outcomes compared to traditional casting, forging and billet machining processes. ARCEMY is the Internet of Things (IoT) and Industry 4.0 enabled to allow manufacturers across aerospace, defense, maritime, manufacturing, mining and oil & gas to become globally competitive. The company also provides metal 3D printing design engineering services, software licensing, technical support, consumable sales and contract manufacturing services.

Alderan Resources Limited

AL8

Alderan Resources Ltd. operates as a mineral exploration, development and project generation company. The company is headquartered in Subiaco, Western Australia and currently employs 4 full-time employees. The company went IPO on 2017-06-09. The firm is engaged in discovering and developing critical metal and gold deposits for mining. The firm owns a portfolio of four exploration projects in Utah, United States. Its projects include Detroit, Valley/Crossroads, Frisco, and White Mountain. Detroit project lies within the Detroit Mining District, approximately 290 (km) southwest of Salt Lake City. White Mountain is a gold exploration project located approximately 300 km south-southwest of Salt Lake City and 25 km southwest from the town of Milford in Utah, United States. The firm owns 24 granted exploration licenses (472 square kilometers (km2)) in seven project areas - Curral de Dentro, Minas Novas, Carai, Catuji, Itaipe, Itambacuri and Governador Valadares. The Projects are located immediately to the south, of the district known as Lithium Valley in the Eastern Lithium Belt of Eastern Brazil.